옵션 체인은 다양한 행사가격과 만기일에 대한 Moleculin Biotech의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Moleculin Biotech에 대한 시장 심리를 평가합니다..

Moleculin Biotech (NASDAQ:MBRX) 주식, 옵션 체인

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Moleculin Biotech Inc

Ambase (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABCP#OTC">ABCP</a>) reported quarterly losses of $(0.02) per share. This is a 60 percent increase over losses of $(0.05) per share from the same period last year.

Earnings

News

ABCP

Ambase Q1 EPS $(0.02) Up From $(0.05) YoY

Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) reported quarterly losses of $(0.34) per share. This is a 100 percent decrease over losses of $(0.17) per share from the same period last year. The company reported $3.39 million in sales this quarter. This is a 1.77 percent increase over sales of $3.33 million the same period last year.

SATL

CORRECTION: Satellogic Q1 EPS $(0.34) Down From $(0.17) YoY, Sales $3.39M Up From $3.33M YoY

McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) has outperformed the market over the past 20 years by 3.89% on an annualized basis producing an average annual return of 12.19%. Currently, McDonald's has a market capitalization of $220.59 billion. 
Buying $1000 In MCD: If an investor had bought $1000 of MCD stock 20 years ago, it would be worth $9,967.39 today based on a price of $308.75 for MCD at the time of writing.
<h3>McDonald's's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747174516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In McDonald's 20 Years Ago Would Be Worth Today

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $20 price target.

Price Target

Analyst Ratings

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Chardan Capital analyst Keay Nakae maintains Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy and maintains $25 price target.

KRRO

Chardan Capital Maintains Buy on Korro Bio, Maintains $25 Price Target

General

EXEL

Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors

Reality competition "Beast Games"<a href="https://www.benzinga.com/general/entertainment/24/03/37809533/mrbeast-confirms-beast-games-on-amazon-prime-video-with-1-000-contestants-5m-prize-its-gonn"> from the mind of</a> content creator MrBeast is returning for two more seasons on Prime Video, the streaming platform from Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
MrBeast says he hopes this time the show doesn't lose him as much money, but he promises to make it bigger than the first season.
What Happened: A first season of "Beast Games" set several records, including 44 Guinness World Records, and had a massive $10 million payout to the winner from 1,000 contestants, but also created a <a href="https://www.benzinga.com/general/entertainment/25/02/43903423/mrbeast-calls-his-amazon-deal-for-beast-games-a-financial-mistake-this-is-the-price-you-have-to-pay">financial loss for MrBeast.</a>
The content creator, also known as Jimmy Donaldson, announced on social media that "Beast Games" has been renewed for two more seasons with Prime Video.
"Y'all are not ready for the big stuff we have planned," MrBeast <a href="https://x.com/MrBeast/status/1922068781058109819">said </a>in the post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Prime video has renewed Beast Games for not one but TWO MORE SEASONS!! Y'ALL ARE NOT READY FOR THE BIG STUFF WE HAVE PLANNED &#x1f970;&#x1f970;&#x1f970; <a href="https://t.co/oc5hWKBEnq">pic.twitter.com/oc5hWKBEnq</a>
&mdash; MrBeast (@MrBeast) <a href="https://twitter.com/MrBeast/status/1922068781058109819?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
A user asked MrBeast how he can make the show "go bigger" without the fear of going bankrupt, while asking about his loss on the first season.
"Going bigger is my specialty, that's the least of my concerns haha. Yeah, ideally don't lose 8 figures though," MrBeast replied.
The first season was the most-watched unscripted series on Prime Video, according to a <a href="https://variety.com/2025/tv/news/mrbeast-beast-games-renewed-two-seasons-prime-video-1236392387/">report </a>from Variety. The series had 50 million viewers in the first 25 days after its Dec. 19 premiere.
MrBeast has 32.5 million followers on X and 394 million subscribers on YouTube, ranking as the top followed account on the video platform.
The popularity of the content creator helped boost viewership for Prime Video and could do the same for two more seasons.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/05/38860861/amazon-betting-on-game-shows-for-streaming-growth-mrbeast-travis-kelce-pop-culture-jeopardy">Amazon Betting On Game Shows For Streaming Growth: MrBeast, Travis Kelce, Pop Culture Jeopardy And More</a>
What's Next: Based on the "Beast Games" <a href="https://www.beastgames.com/">website</a>, it looks like season 2 is still casting. The website says casting is open to people aged 18 or older who can legally travel and re-enter the U.S. for up to six consecutive weeks during the period of May to July 2025.
Contestants must also be free of any obligations including personal, family or work during the designated time period of filming for the show. Another interesting casting nugget is that any current candidates for public office or people intending to run for public office within one year as of July 1, 2026, can not participate in the show.
To get cast on the second season of "Beast Games," contestants need to submit their information along with a one-minute video about themselves that includes answers to some of the following questions:
<ul class="wp-block-list">
<li>"What was your favorite challenge from BEAST GAMES Season 1, and why?</li>
<li>"Who was your favorite contestant from Season 1, and what made them stand out to you?</li>
<li>"What makes you an unforgettable competitor?"</li>
<li>"What would you do with $5,000,000?"</li>
</ul>
Contestants on "Beast Games" are tested with challenges that are physical, mental and social and are also offered bribes to leave the game along the way.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44543735/mrbeast-is-writing-a-squid-game-style-thriller-and-media-companies-are-ready-to-bid-eight-figures-for-the-rights">MrBeast Is Writing A &#8216;Squid Game&#8217; Style Thriller And Media Companies Are Ready To Bid Eight-Figures For The Rights</a></li>
</ul>
Photo: Joe Seer via Shutterstock

Entertainment

Media

AMZN

MrBeast Teases Two More Seasons Of 'Beast Games' After Losing Millions: 'Ideally Don't Lose 8 Figures'

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $14 price target.

COYA

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Mannatech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEX#NASDAQ">MTEX</a>) reported quarterly losses of $(0.80) per share. This is a 226.98 percent decrease over earnings of $0.63 per share from the same period last year. The company reported $26.56 million in sales this quarter. This is a 9.63 percent decrease over sales of $29.39 million the same period last year.

MTEX

Mannatech Q1 EPS $(0.80) Down From $0.63 YoY, Sales $26.56M Down From $29.39M YoY

Wells Fargo analyst Yanan Zhu downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Overweight to Equal-Weight and lowers the price target from $11 to $0.1.

Downgrades

AFMD

Wells Fargo Downgrades Affimed to Equal-Weight, Lowers Price Target to $0.1

Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) reported quarterly losses of $(0.09) per share. This is a 91.89 percent increase over losses of $(1.11) per share from the same period last year. The company reported $343.00 thousand in sales this quarter. This is a 435.94 percent increase over sales of $64.00 thousand the same period last year.

WATT

UPDATE: Energous Q1 Adj. EPS $(0.09) Up From $(1.11) YoY, Sales $343.00K Up From $64.00K YoY

Fifth District Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDSB#NASDAQ">FDSB</a>) reported quarterly earnings of $0.02 per share. The company reported $3.20 million in sales this quarter.

FDSB

Fifth District Bancorp Q1 EPS $0.02, Sales $3.20M

Electra Battery Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>) reported quarterly losses of $(0.61) per share. This is a 4.69 percent increase over losses of $(0.64) per share from the same period last year.

ELBM

Electra Battery Materials Q1 EPS $(0.61) Up From $(0.64) YoY

MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) reported quarterly losses of $(0.39) per share. This is a 71.53 percent increase over losses of $(1.37) per share from the same period last year.

MEIP

MEI Pharma Q3 GAAP EPS $(0.39) Up From $(1.37) YoY

Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) reported $12.81 million in sales this quarter. This is a 10.66 percent increase over sales of $11.57 million the same period last year.

BIYA

Baiya International Group FY24 EPS $0.00 Up From $(0.10) YoY, Sales $12.81M Up From $11.57M YoY

Scotiabank analyst Orest Wowkodaw maintains Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) with a Sector Outperform and raises the price target from C$12 to C$12.5.

TSX:HBM

Scotiabank Maintains Sector Outperform on Hudbay Minerals, Raises Price Target to C$12.5

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.15, with a high estimate of $8.00 and a low estimate of $5.00. Observing a downward trend, the current average is 13.38% lower than the prior average price target of $7.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1747173673_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive GoodRx Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.25</td>
<td>$6.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to GoodRx Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GoodRx Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of GoodRx Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of GoodRx Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GDRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GoodRx Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind GoodRx Holdings</h2>
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
<h3>Unraveling the Financial Story of GoodRx Holdings</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining GoodRx Holdings's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.57% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: GoodRx Holdings's net margin excels beyond industry benchmarks, reaching 5.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): GoodRx Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 1.6%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): GoodRx Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.82% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: GoodRx Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.83, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GDRX

Demystifying GoodRx Holdings: Insights From 5 Analyst Reviews

5 analysts have shared their evaluations of Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $20.2, with a high estimate of $23.00 and a low estimate of $18.00. A decline of 1.94% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747173665_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Plains All American's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Plains All American. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Plains All American compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Plains All American's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Plains All American's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PAA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Plains All American analyst ratings.</a>
<h2>Unveiling the Story Behind Plains All American</h2>
Plains All American Pipeline LP through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and barges or railcars. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminalling. It generates the majority of its revenue from the Crude Oil segment.
<h3>Breaking Down Plains All American's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Plains All American's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 0.13%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Plains All American's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.86%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Plains All American's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.53%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Plains All American's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.28%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.93, Plains All American adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Plains All American Stock

AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from the same period last year.

Earnings Misses

ANTX

AN2 Therapeutics Q1 GAAP EPS $(0.35) Misses $(0.26) Estimate

Ratings for Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.29, a high estimate of $10.00, and a low estimate of $2.00. This current average has decreased by 39.05% from the previous average price target of $10.32. 
<img src="https://www.benzinga.com/files/images/story/2025/1747173657_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Fluence Energy among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Sell</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Dimple Gosai</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fluence Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Fluence Energy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Fluence Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Fluence Energy's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FLNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fluence Energy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Fluence Energy: A Closer Look</h2>
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
<h3>Fluence Energy's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Fluence Energy's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -30.74% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Fluence Energy's net margin is impressive, surpassing industry averages. With a net margin of -7.19%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.78%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Fluence Energy's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.0, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Moleculin Biotech

Moleculin Biotech (MBRX) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌